|Awarded On||March 29, 2012|
|Title||Development of therapeutic vaccines/drugs against prostate cancer by Blocking immune suppression|
|Award Mechanism||Bridging the Gap: Early Translational Research Awards|
|Institution/Organization||The Methodist Hospital Research Institute|
|Principal Investigator/Program Director||Rongfu Wang|
Harnessing the immune system to eradicate malignant cells is a promising approach to cancer therapy. Recent FDA approval of sipuleucel-T (Provenge) for the treatment of metastatic prostate cancer and ipilimumab (Yervoy) for the treatment of melanoma represents milestones in the field of cancer immunotherapy. However, the clinical benefits reported for these agents have fallen far short of complete cures. Increasing evidence indicates that T cell-mediated immune suppression at tumor sites is a major obstacle to improving therapeutic efficacy of cancer vaccines and drugs. In efforts to overcome this barrier, we show that stimulation of human Toll-like receptor 8 with a Poly-Guanosine oligonucl...